Novartis India
Novartis India Performance
Day Range
- Low 714
- High 720.4
52 Week Range
- Low 537
- High 909
- Open Price720.2
- Previous Close718.2
- Volume2509
Start SIP in Novartis India
Start SIPNovartis India Investment Rating
-
Master Rating:
-
Novartis India has an operating revenue of Rs. 348.42 Cr. on a trailing 12-month basis. An annual revenue growth of 1% is not great, Pre-tax margin of 30% is great, ROE of 13% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 5% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 32 which is a POOR score indicating inconsistency in earnings, a RS Rating of 30 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 112 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 91 | 76 | 80 | 102 | 121 | 98 |
Operating Expenses Qtr Cr | 73 | 67 | 73 | 85 | 89 | 93 |
Operating Profit Qtr Cr | 17 | 9 | 8 | 16 | 32 | 6 |
Depreciation Qtr Cr | 2 | 2 | 1 | 1 | 1 | 1 |
Interest Qtr Cr | 0 | 0 | 0 | 0 | 1 | 0 |
Tax Qtr Cr | 8 | -2 | 7 | 3 | 4 | -8 |
Net Profit Qtr Cr | 20 | 25 | 8 | 18 | 52 | -23 |
Novartis India Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 3
- Bearish Moving Average
- ___
- 13
- 20 Day
- ₹733.64
- 50 Day
- ₹740.16
- 100 Day
- ₹731.18
- 200 Day
- ₹709.77
- 20 Day
- ₹732.52
- 50 Day
- ₹744.39
- 100 Day
- ₹751.44
- 200 Day
- ₹686.26
Novartis India Resistance and Support
Resistance | |
---|---|
First Resistance | ₹725.7 |
Second Resistance | ₹733.2 |
Third Resistance | ₹737.55 |
RSI | 38.47 |
MFI | 59.55 |
MACD Single Line | -1.43 |
MACD | -2.5 |
Support | |
---|---|
First Resistance | ₹713.85 |
Second Resistance | ₹709.5 |
Third Resistance | ₹702 |
Novartis India Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 12,835 | 772,410 | 60.18 |
Week | 15,952 | 831,918 | 52.15 |
1 Month | 19,539 | 966,192 | 49.45 |
6 Month | 36,535 | 1,838,829 | 50.33 |
Novartis India Result Highlights
Novartis India Synopsis
NSE-Medical-Diversified
Novartis is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company’s Total Operating Revenue is Rs. 378.74 Cr. and Equity Capital is Rs. 12.34 Cr. for the Year ended 31/03/2023. Novartis India Ltd. is a Public Limited Listed company incorporated on 13/12/1947 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24200MH1947PLC006104 and registration number is 006104.Market Cap | 1,773 |
Sales | 348 |
Shares in Float | 0.72 |
No of funds | 43 |
Yield | 1.39 |
Book Value | 2.29 |
U/D Vol ratio | 1.1 |
LTDebt / Equity | |
Alpha | 0.02 |
Beta | 0.36 |
Novartis India
Owner Name | Jun-23 | Mar-23 | Dec-22 | Sep-22 |
---|---|---|---|---|
Promoters | 70.68% | 70.68% | 70.68% | 70.68% |
Mutual Funds | ||||
Insurance Companies | 0.74% | 0.76% | 0.76% | 0.76% |
Foreign Portfolio Investors | 0.23% | 0.17% | 0.17% | 0.17% |
Financial Institutions/ Banks | 0.01% | 0.01% | 0.01% | 0.01% |
Individual Investors | 23.09% | 23.04% | 23.01% | 23.02% |
Others | 5.25% | 5.34% | 5.37% | 5.36% |
Novartis India Management
Name | Designation |
---|---|
Mr. Christopher Snook | Chairman |
Mr. Sanjay Murdeshwar | Vice Chairman & Mng.Director |
Ms. Shilpa Joshi | WholeTime Director & CFO |
Ms. Sandra Martryes | Independent Director |
Mr. Jai Hiremath | Independent Director |
Mr. Sanker Parameswaran | Independent Director |
Novartis India Forecast
Price Estimates
Novartis India Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-07-26 | Quarterly Results | |
2023-05-10 | Audited Results, Final & Special Dividend | |
2023-02-08 | Quarterly Results | |
2022-11-09 | Quarterly Results | |
2022-07-27 | Quarterly Results |
- Company Name
- CMP
- Chg(%)
- Company Name
- CMP
- Chg(%)
- Bajaj Finance
- 7759
- -1.4
- B P C L
- 347
- -1.3
- ICICI Bank
- 937
- -1.3
- Tata Steel
- 127
- -1.2
- Titan Company
- 3227
- -1.1
Novartis India FAQs
What is Share Price of Novartis India ?
Novartis India share price is ₹716 As on 27 September, 2023 | 10:44
What is the Market Cap of Novartis India ?
The Market Cap of Novartis India is ₹1770 Cr As on 27 September, 2023 | 10:44
What is the P/E ratio of Novartis India ?
The P/E ratio of Novartis India is 24.8 As on 27 September, 2023 | 10:44
What is the PB ratio of Novartis India ?
The PB ratio of Novartis India is 2.3 As on 27 September, 2023 | 10:44